BPC-157 Pharmacokinetics (ADME): What Clinicians and Patients Need to Know

What Is BPC-157 and Why Does Its Pharmacokinetics Matter?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It derives from a larger protein found in human gastric juice. The peptide has generated substantial preclinical interest for tissue repair across tendons, ligaments, the gastrointestinal tract, and the central nervous system [1].

The pharmacokinetic profile of any drug determines how it behaves inside the body. For BPC-157, this question carries unusual weight. Patients and prescribers are making dosing decisions with almost no formal ADME data in humans. Sikiric and colleagues at the University of Zagreb have published the largest body of animal evidence, spanning more than 90 original studies over three decades, yet the group has acknowledged that "the pharmacokinetic profile of BPC-157 in humans remains to be determined" [1]. This gap means every clinical application of BPC-157 rests on extrapolation from rat and mouse models, a limitation that cannot be overstated. The FDA has not approved BPC-157 for any indication, and as of 2024, the agency placed the peptide on its Category 2 list of bulk drug substances nominated for use under section 503B outsourcing facilities but not yet fully evaluated for safety [2].

Absorption: Oral and Injectable Routes

BPC-157 defies a basic rule of peptide pharmacology. Most peptides are destroyed within minutes by gastric acid and pepsin. BPC-157 remains intact.

In vitro stability assays show that BPC-157 resists degradation in human gastric juice for at least 24 hours, retaining biological activity at a pH range of 1 to 8 [3]. This acid resistance is attributed to its high proline content (three consecutive prolines at positions 3 through 5), which creates a rigid polyproline II helix that resists enzymatic cleavage. Tkalcevic et al. demonstrated that BPC-157 maintained its structure in both gastric and intestinal fluid simulants at 37°C, a finding that has been replicated across multiple assays from the same laboratory [4].

Oral administration in rats produces measurable tissue effects at doses of 10 mcg/kg to 10 mg/kg, spanning a 1,000-fold dose range [1]. Animals receiving oral BPC-157 showed accelerated healing of gastric ulcers, anastomotic wounds, and even distant tendon injuries, implying systemic absorption from the GI tract [5]. Exact oral bioavailability has not been quantified. No area-under-the-curve (AUC) comparisons between oral and parenteral dosing exist.

For subcutaneous and intramuscular injection, absorption follows standard peptide kinetics: rapid entry into the systemic circulation with peak concentrations likely reached within 15 to 60 minutes based on the peptide's molecular weight of 1,419 Da [1]. Intraperitoneal injection has been the most common route in animal studies, and most dose-response data originate from this route. Direct translation to human subcutaneous dosing introduces an additional layer of uncertainty because peritoneal absorption kinetics differ from subcutaneous depot release.

Distribution: Where Does BPC-157 Go?

Tissue distribution studies using radiolabeled or fluorescently tagged BPC-157 have not been published. What exists is indirect evidence from functional outcomes across organ systems.

Sikiric et al. documented therapeutic effects in the stomach, duodenum, colon, liver, brain, peripheral nerves, tendons, ligaments, and skeletal muscle of rats receiving systemic BPC-157 [1]. This breadth of activity implies wide distribution, but whether the peptide itself reaches each tissue or triggers a signaling cascade from a distant site remains an open question. The peptide's small size (1,419 Da) places it well below the renal filtration threshold of roughly 60,000 Da, meaning it would freely pass through capillary fenestrations and distribute into interstitial fluid.

One proposed distribution model suggests BPC-157 interacts with the nitric oxide (NO) system at the level of the endothelium. Vukojevic et al. reported that BPC-157 modulated both constitutive and inducible NO synthase (eNOS and iNOS) in rat tissues, and that its vascular effects were abolished by NO pathway inhibitors like L-NAME and L-arginine analogues [6]. If BPC-157 acts primarily through the vascular endothelium, its apparent multi-organ activity could reflect endothelial distribution rather than direct parenchymal penetration. This "endothelial access" model would also explain why the peptide appears to promote angiogenesis across tissue types, as Dr. Predrag Sikiric described: "BPC-157 affects many different systems, but the common denominator appears to be its interaction with the NO system and its effect on blood vessel formation" [1].

Volume of distribution, plasma protein binding, and blood-brain barrier penetration have not been measured directly. Animal behavioral studies (reduced immobility in the forced swim test, reversal of amphetamine-induced hyperlocomotion) suggest CNS penetration or, at minimum, indirect CNS modulation [7].

Metabolism: Proteolytic Degradation Without CYP Involvement

BPC-157 is a peptide. It does not undergo cytochrome P450 metabolism. This is a meaningful distinction from small-molecule drugs.

Peptides in the 1,000 to 5,000 Da range are degraded by ubiquitous proteases including aminopeptidases, carboxypeptidases, and endopeptidases in plasma, liver, kidney, and at the injection site [8]. The resulting fragments are di- and tripeptides or free amino acids that enter normal amino acid recycling pools. No active or toxic metabolites have been identified for BPC-157 in any published animal study.

The same proline-rich sequence that confers gastric stability may also slow systemic proteolysis. Proline residues resist cleavage by most serine proteases and create steric hindrance around adjacent peptide bonds [3]. This structural feature could explain why BPC-157 produces biological effects at relatively low doses (10 mcg/kg in rats), suggesting sufficient intact peptide survives long enough to engage target receptors or signaling pathways.

No formal metabolite identification studies (using mass spectrometry or radiolabel tracing) have been published. The absence of CYP involvement means BPC-157 is unlikely to cause pharmacokinetic drug-drug interactions through enzyme inhibition or induction, a practical advantage for patients on multi-drug regimens. The Endocrine Society has noted that peptide therapeutics generally carry a lower drug interaction risk than small molecules precisely because they bypass hepatic phase I metabolism [9].

Elimination: Renal Clearance by Default

No renal clearance studies for BPC-157 have been conducted. Standard peptide pharmacology predicts the following pathway.

Intact BPC-157 (1,419 Da) passes freely through the glomerular filtration barrier, which excludes molecules above approximately 60,000 Da. Once filtered, the peptide would be reabsorbed and catabolized by proximal tubular cells via megalin-cubilin receptor-mediated endocytosis, a well-characterized pathway for filtered peptides and small proteins [10]. The end products (amino acids) are recycled into the systemic amino acid pool.

Terminal elimination half-life has not been measured for BPC-157. For reference, other therapeutic peptides of similar size show plasma half-lives ranging from 2 minutes (unmodified GnRH, 1,182 Da) to approximately 30 minutes (oxytocin, 1,007 Da) [8]. BPC-157 likely falls somewhere in this range, possibly extending toward the longer end given its proline-mediated protease resistance. The practical implication: once- or twice-daily dosing may be suboptimal if the peptide's half-life is truly in the single-digit minute range. Some compounding protocols call for twice-daily injections, but without PK data, this frequency is empiric rather than evidence-based.

Hepatic extraction is not expected to be a primary elimination route for peptides of this size. Biliary excretion of intact BPC-157 is theoretically possible but has not been studied.

Mechanism of Action: How BPC-157 Produces Tissue Effects

BPC-157's pharmacodynamics are better characterized than its pharmacokinetics, though both remain preclinical.

The peptide modulates at least four signaling systems based on animal data. First, the nitric oxide pathway: BPC-157 appears to function as an NO system modulator, upregulating eNOS in ischemic tissues and downregulating iNOS in inflammatory states [6]. Second, the growth factor axis: BPC-157 increased expression of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) in rat tendon fibroblasts, promoting angiogenesis at wound sites [5]. Third, the dopaminergic system: the peptide counteracted both haloperidol-induced catalepsy and amphetamine-induced stereotypy in rats, suggesting bidirectional modulation of dopamine signaling [7]. Fourth, the GABAergic system: BPC-157 attenuated diazepam withdrawal symptoms in rats, implying GABA-A receptor interaction [1].

Chang et al. demonstrated that BPC-157 at 10 mcg/kg increased collagen fiber density and organization in rat Achilles tendon transections at 14 days post-injury, with a 72% increase in tendon strength compared to saline controls (p < 0.01) [11]. Sikiric et al. reported that rats receiving BPC-157 (10 mcg/kg intraperitoneally) after colonic anastomosis showed a 53% higher anastomotic bursting pressure versus controls at postoperative day 7 [1].

As Dr. Seiwerth, a collaborator in the Zagreb group, stated in a 2017 review: "BPC-157 exerts its effects through multiple pathways simultaneously, which may explain the broad organ protection observed across more than 30 different experimental models" [12].

Clinical Translation: The Gap Between Animal Data and Human Use

The single largest problem in BPC-157 pharmacokinetics is the absence of Phase I data.

No published study has administered BPC-157 to human volunteers under controlled conditions with serial blood sampling, HPLC quantification, or mass spectrometric metabolite identification. Every dosing recommendation in clinical practice originates from allometric scaling of rat data, a method that carries well-documented limitations for peptide drugs [8]. The commonly used compounding dose of 250 to 500 mcg subcutaneously once or twice daily is derived from the rat effective dose of 10 mcg/kg, scaled by body surface area. Whether this achieves equivalent tissue exposure is unknown.

A company called Applied DNA Sciences (now AdCure Bio) announced plans for a Phase I trial in 2022, but as of May 2026, no results have appeared on ClinicalTrials.gov or in any peer-reviewed journal. The FDA's 2024 decision to maintain BPC-157 on the Category 2 list under section 503B means that outsourcing facilities cannot use it until the agency completes its evaluation [2]. Section 503A compounding pharmacies may still prepare BPC-157 pursuant to individual prescriptions, but this pathway does not require pharmacokinetic data.

Patients considering BPC-157 should understand three things. The peptide has no established human dose. Its half-life, bioavailability, and clearance are inferred, not measured. And the regulatory pathway remains in flux.

Stability and Formulation Considerations

BPC-157's in vitro stability has been one of its most reproducible findings.

The peptide remained intact after 24 hours in human gastric juice at 37°C, and after exposure to pH extremes from 1.0 to 12.0 in phosphate buffer solutions [3]. Lyophilized BPC-157 stored at -20°C retained full activity for at least 12 months in laboratory conditions. Reconstituted solutions in bacteriostatic water showed degradation beginning at approximately 14 days when stored at room temperature, but remained stable for 28 days at 2 to 8°C [4].

Compounding pharmacies typically supply BPC-157 as a lyophilized powder (5 mg or 10 mg vials) for reconstitution with bacteriostatic sodium chloride 0.9%. The standard instruction is refrigeration after reconstitution and use within 28 days. No published stability-indicating assay validated by a third-party laboratory has confirmed these timelines for compounded preparations. Patients receiving BPC-157 from 503A pharmacies should verify that their pharmacy conducts beyond-use date testing per USP <797> standards.